[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gulf-war-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gulf-war-syndrome":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,44,74,98,123,154,178,205,234],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100613436","pycnogenol-french-maritime-pine-bark-for-the-treatment-of-gulf-war-illness-100613436",false,"NCT07266571","Pycnogenol (French Maritime Pine Bark) for the Treatment of Gulf War Illness","Inclusion Criteria:\n\n* Meet the Kansas GWI case definition\n* Meet the CDC GWI case definition\n* Able to commit to a 12-month study\n* Male\n* Participants will be individuals in our Gulf War database who have already completed our other botanical trial, Curcumin, Resveratrol, and Stinging Nettle as Treatments for Gulf War Illness (NCT05377242).\n\nExclusion Criteria:\n\n* Currently involved in another experimental treatment study\n* Female\n* Have a blood clotting disorder\n* Reported diagnosis of diabetes with a A1C greater than 9\n* Use of contraindicated medications (see below):\n* Anticoagulants (such as warfarin, heparin, etc.)\n* Lithium\n* Tacrolimus (Prograf)\n* Cancer medications (Alkylating agents, antitumor antibiotics, Topoisomerase I inhibitors, Tamoxifen)\n* Daily Use of Antiplatelet agents (e.g. aspirin, clopidogrel)\n* Nitroglycerin\n* Hypotension\n* Need for surgery during study period.","MALE","18 Years",{"count":18,"type":19},20,"ESTIMATED","INTERVENTIONAL",[22],"NA","The purpose of this research study is to determine how pycnogenol may reduce Gulf War Illness (GWI) symptom severity. The study will also examine the safety of this treatment and determine the optimal dosage. The investigators believe that GWI involves inflammation in the body and brain that causes fatigue, pain, cognitive disruption, and other symptoms. Botanicals that reduce inflammation may help treat GWI.",[25],"Gulf War Syndrome",[27,28,29,30],"Gulf War Illness","Pycnogenol","Botanical","French Maritime Pine Bark","NOT_YET_RECRUITING","2026-06-15",{"date":34,"type":35},"2026-06-17","ACTUAL",{"date":37,"type":19},"2026-08-01",{"date":39,"type":19},"2027-08-01",{"name":41,"class":42},"University of Alabama at Birmingham","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":52,"minAge":16,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":20,"phases":55,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100466556","phase-2-growth-hormone-replacement-in-veterans-with-gwi-and-aghd-gwit-100466556","NCT05355272","Growth Hormone Replacement in Veterans With GWI and AGHD (GWIT)","Growth Hormone Replacement Therapy in Veterans With Gulf War Illness and Adult Growth Hormone Deficiency","GWIT","Inclusion Criteria:\n\n1. veteran of the Gulf War conflict with a history of deployment to Operation Desert Storm or Desert Shield between 1990-91\n2. age less than or equal to 64 years old\n3. have a diagnosis of Gulf War Illness assessed by study investigators\n4. have adult growth hormone deficiency diagnosed by glucagon stimulation test (cut point 3.0 mcg\u002FL if BMI is less than or equal to 25 or 1.0 mcg\u002FL if BMI is greater than 25)\n5. 4-week stability on any psychotropic medications\n6. 3-month stability on all hormone treatments\n7. able and willing to provide informed consent to participant in the study and complete study protocol\n\nExclusion Criteria:\n\n1. history of a psychiatric disorder with substantial impact on functional status or quality of life (e.g., schizophrenia, schizoaffective disorder, bipolar, or other psychotic disorder)\n2. history of neurologic disorder other than traumatic brain injury with substantial impact on the quality of life\n3. other known cause for growth hormone deficiency (GHD) including history of childhood onset GHD, hypothalamic\u002Fpituitary disease, history of brain radiation, or genetic mutations known to lead to GHD\n4. active suicidal ideation as determined by a score of 2 points or higher on the Columbia Suicide Severity Rating Scale\n5. suicidal behavior in the past 6 months\n6. contraindication to recombinant human growth hormone (rhGH) such as hypersensitivity to rhGH or any of the components of the supplied product\n7. acute medical illness, active infection, cancer, or decompensated chronic medical illness (e.g., decompensated diabetes mellitus, congestive heart failure, chronic obstructive pulmonary disease)\n8. evidence of substance use disorder in the past 6 months other than mild alcohol or cannabis use disorder diagnosed by clinician at time of screening.\n9. urine toxicology evidence of illicit drug use (excluding cannabis) within the past 90 days prior to screening\n10. BMI \\> 35 or body weight \\> 350 lbs\n11. abnormal pituitary anatomy documented by an MRI using a Sella protocol\n12. women who are pregnant or of child-bearing potential who are unable\u002Funwilling to use one of the following barrier contraceptives: condoms, diaphragm, cervical cap, or intrauterine device\n13. current use of the following: growth hormone, estrogen or estrogen-like dietary supplements, hormonal contraceptives, progestin, insulin growth factor 1 (IGF-1), or chronic glucocorticoid use in supraphysiologic doses\n\n15\\) currently enrolled in any other interventional drug trials unless prior approval is provided by the study chairs and the study sponsor","ALL","64 Years",{"count":18,"type":19},[56],"PHASE2","The goal of the GWIT Study is to assess whether growth hormone replacement therapy is a safe and effective treatment for veterans with Gulf War Illness (GWI) and adult growth hormone deficiency (AGHD). The main questions the study aims to answer are:\n\n1. Is growth hormone effective at reducing fat in the trunk of the body and symptoms of GWI among veterans with GWI and growth hormone deficiency?\n2. Do the results of the study suggest there is merit in pursuing a larger trial to examine the efficacy of growth hormone as a treatment for growth hormone deficiency among veterans with Gulf War Illness?\n\nTo determine eligibility for the study, veterans will be asked to complete several assessments including questionnaires, blood tests, and a scan of the brain. Participants who qualify for the study will receive recombinant human growth hormone for 6-months. A body composition scan will be performed at Day1, Day 90, and Day 180 of the intervention. Questionnaires and cognitive tests will also be collected before and after the trial.",[25,59],"Adult Growth Hormone Deficiency",[61,62],"recombinant human growth hormone","growth hormone replacement therapy","RECRUITING","2026-05-05",{"date":66,"type":35},"2026-05-08",{"date":68,"type":35},"2024-03-11",{"date":70,"type":19},"2027-07-01",{"name":72,"class":42},"Baylor College of Medicine",2,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":52,"minAge":80,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":20,"phases":83,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":43},"100555676","phase-3-coenzyme-q10-for-gulf-war-illness-a-replication-study-100555676","NCT06515184","Coenzyme Q10 for Gulf War Illness: A Replication Study","Inclusion Criteria:\n\n* Meets both CDC and Kansas deployment and symptom inclusion criteria.\n* Does not have a disqualifying condition.\n* Able to travel to a local Quest facility for study blood draws.\n* Adequate internet access to allow ZoomPro visit participation and remote survey completion.\n* Health prior to the Gulf War rated as \"very good\" or \"excellent\" (to exclude persons who may have had other health conditions with different mechanisms as the cause of their symptoms).\n* Willing to defer initiation of discretionary treatments or supplements during the expected course of study participation.\n\nExclusion Criteria:\n\n* Participating in another clinical trial.\n* Still-evolving adverse effects following another medication or health condition, such as covid or fluoroquinolone use.\n* On Coumadin\u002F warfarin.\n* Unable to participate for the required duration of the study.","50 Years",{"count":82,"type":19},192,[84],"PHASE3","The purpose of this study is to assess whether a high quality preparation of ubiquinone (coenzyme Q10) benefits symptoms, function, and quality of life in veterans with Gulf War illness.",[25,87,88],"Persian Gulf Syndrome","Mitochondrial Disorder, Respiratory Chain","2026-04-27",{"date":91,"type":35},"2026-05-01",{"date":93,"type":35},"2024-09-13",{"date":95,"type":19},"2027-12",{"name":97,"class":42},"University of California, San Diego",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":52,"minAge":105,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":20,"phases":109,"briefSummary":110,"conditions":111,"keywords":112,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":43},"100604571","cranial-electrotherapy-stimulation-and-brain-imaging-for-gulf-war-syndrome-100604571","NCT07151248","Cranial Electrotherapy Stimulation and Brain Imaging for Gulf War Syndrome","ELECTRIG: Evaluating Effects of Cranial Electrical Stimulation Therapy With Responsive Imaging in Gulf War Illness Pain and Comorbid Symptoms","Inclusion Criteria:\n\n1. Subjects must be male and female age 40-80 years old\n2. Meet criteria for GWVI based on the CDC and Kansas Criteria for GWVI.\n\n   * CDC: 1 or more from at least 2 of the following categories for ≥ 6 months): 1) fatigue 2) mood and cognition (symptoms of feeling depressed, difficulty in remembering or concentrating, feeling moody, feeling anxious, trouble in finding words, or difficulty in sleeping) 3) musculoskeletal (symptoms of joint pain, joint stiffness, or muscle pain\n   * Kansas: 3 of 6 domains: 1) fatigue and sleep problems 2) pain symptoms 3) neurologic, cognitive, or mood symptoms 4) gastrointestinal symptoms 5) respiratory symptoms 6) skin symptoms chronic since 1990. Symptom reporting must be in the absence of diagnosed exclusionary conditions; only respondents who have at least 1 moderately severe symptom or 2 or more symptoms within a group were considered to have a high level of symptoms in the group.\n3. Subjects must self-report consistent, daily pain (greater than or equal to 4 on the DVPRS) \\>90 days (prior to enrollment)\n4. Subjects must have intact skin free of infection at the site of electrode placement (earlobe).\n5. Subjects must be willing to participate and understand the consent.\n6. Subjects must be right-handed to provide consistency in brain structure and function.\n\nExclusion Criteria:\n\n1. Subjects must not be currently pregnant since effects of fMRI and electrical current on the developing fetus are not well-known.\n2. Subjects must not have a history of drug abuse or severe, uncontrolled psychiatric illness such as schizophrenia or major depressive disorder with suicidal ideation.\n3. Subjects must not have psoriasis vulgaris or other skin conditions that may increase the risk of infection at the implantation site.\n4. Subjects must not introduce new medications or treatments for symptoms during the study to prevent confounding results.\n5. Subjects must not have severe anxiety, claustrophobia, or other conditions that may prevent their ability to lie at rest in an MRI scanner. This will be determined after discussion with the patient regarding their own perceived ability to lie at rest in an MRI scanner without the use of additional sedating medications.\n6. Subjects must not have an implanted electrical device such as a surgically placed vagal stimulator, pacemaker, or spinal pain pump, which are not compatible with MRI.\n7. Subjects must not have a history of seizures or neurologic conditions that may alter the structure of the brain.\n8. Subjects must not be allergic to the metals used in electrodes for CES stimulation.\n9. Subjects must not have a diagnosed autoimmune disease that better explains pain symptoms.","40 Years","80 Years",{"count":108,"type":19},130,[22],"The main goal of the proposed study is to critically evaluate a nonpharmacological and readily available therapy, cranial electrical stimulation (CES) using Alpha-Stim™, and to discover the brain function mechanisms underlying Gulf War Illness-related Headache and Pain (GWI-HAP) and treatment response to CES.\n\nFor this objective, the investigators will employ an adaptive trial design as well as a neuroimaging technique using MRI, which has become the pre-eminent technique for assessing the integrity of brain function, connectivity, and organization in healthy brain and pathology.",[25],[113],"Gulf War Illness Headaches and Pain","2026-04-18",{"date":116,"type":35},"2026-04-22",{"date":118,"type":35},"2025-09-26",{"date":120,"type":19},"2029-09",{"name":122,"class":42},"Emory University",{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":127,"acronym":128,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":52,"minAge":16,"maxAge":4,"enrollmentInfo":130,"targetDuration":4,"studyType":20,"phases":132,"briefSummary":133,"conditions":134,"keywords":139,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":153},"100571143","confirming-the-effects-of-acupuncture-treatments-to-relieve-symptoms-of-gulf-war-illness-100571143","NCT06716411","Confirming the Effects of Acupuncture Treatments to Relieve Symptoms of Gulf War Illness","CARE","Inclusion Criteria:\n\n* Deployed to the Gulf Theater of operations (as defined by 38 CFR 3.317, includes Iraq, Kuwait, Saudi Arabia, Bahrain, Qatar, the United Arab Emirates, Oman, the Gulf of Aden, the Gulf of Oman, the Persian Gulf, the Arabian Sea, the Red Sea, and the airspace above all of these locations) between August 1990 and the present date\n* Have at least 2 of the following symptoms from the 3 CDC clusters of symptom that have lasted for more than 6 months. Each symptom cluster must be characterized as mild-moderate or severe, with at least one symptom in each cluster required to be severe. The clusters are:\n\nA. Fatigability: fatigue 24 hours or more after exertion B. Mood and Cognition: feeling depressed; feeling irritable; difficulty thinking or concentrating; feeling worried, tense, anxious; problems finding words; or problems getting to sleep C. Musculoskeletal: joint pain or muscle pain\n\nExclusion Criteria:\n\n* Currently enrolled in another clinical trial\n* Have another disease that likely could account for the symptoms, as determined by our Medical Monitor\n* Severe psychiatric illness (in the last 2 years psychiatric hospitalization, suicidal attempt, alcohol or substance abuse, use of antipsychotic medication) as measured by the Primary Care Evaluation of Mental Disorder (Prime MD).\n* Unable to complete the protocol on based on the evaluation of the Medical Monitor.",{"count":131,"type":19},200,[22],"This unblinded Phase II clinical trial will test the effects of individualized acupuncture treatments offered in extant acupuncture practices in the community; practitioners will have had at least 5 years of experience plus additional training provided by the study. Veterans with diagnosed symptoms of Gulf War Illness will be randomized to either six months of biweekly acupuncture treatments (group 1, n=100) or 2 months of waitlist followed by weekly acupuncture treatments (group 2, n=100). Measurements were taken at baseline, 2, 4 and 6 months. The primary outcome is the SF-36 physical component scale score (SF-36P).",[87,25,135,136,137,138],"Multiple Chronic Illnesses","Occupational Diseases","War-Related Injuries","Wounds and Injuries",[140,27,141,142,143],"Acupuncture","Complex Medical Illness","Chronic Multisymptom Illness","Veteran","2026-04-02",{"date":146,"type":35},"2026-04-03",{"date":148,"type":35},"2026-02-03",{"date":150,"type":19},"2028-09-30",{"name":152,"class":42},"University of Utah",10,{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":160,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":52,"minAge":80,"maxAge":162,"enrollmentInfo":163,"targetDuration":4,"studyType":20,"phases":165,"briefSummary":167,"conditions":168,"keywords":169,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":175,"leadSponsor":177,"locationsCount":43},"100515500","phase-1-clinical-evaluation-of-montelukast-in-veterans-with-gulf-war-illness-100515500","NCT05992311","Clinical Evaluation of Montelukast in Veterans With Gulf War Illness","Clinical Evaluation of Montelukast on Cognitive and Mood Dysfunction and Neuroinflammation in Veterans With Gulf War Illness (GWI)","(GWI)","Inclusion Criteria:\n\n* Gulf War Veterans of the U.S. military deployed on military orders to the Persian Gulf Region between August 2, 1990, and December 31, 1991\n* Diagnosed with GWI according to the CDC and modified Kansas criteria as recommended by the Institute of Medicine (IOM), that is, endorse multiple or moderate-to-severe symptoms, with symptom onset during or after deployment to the Persian Gulf region in 1990-1991, persisting for six months or longer, in at least 3 of 6 domains:\n\n  1. fatigue\u002Fsleep disturbances\n  2. neurological\u002Fcognitive\u002Fmood symptoms\n  3. somatic pain\n  4. gastrointestinal problems\n  5. respiratory symptoms\n  6. skin symptoms\n* Self-reported cognitive dysfunction based on a T-score of 40 or less on the PROMIS v2.0 Cognitive Function 8a short form\n* Be able to:\n\n  * provide written consent and be able to communicate with the research team in verbal and written English\n  * attend the two in-person study encounters\n  * have reliable telephone service for the eight weekly telephone encounters\n\nExclusion Criteria:\n\n* Diagnosed by a physician with any chronic condition that may explain their profile of symptoms or prevent their ability to accurately report them including:\n\n  * chronic autoimmune conditions\n  * systemic inflammatory conditions\n  * cancer not in remission at least 5 years\n  * congestive heart failure\n  * anemia\n  * multiple sclerosis\n  * amyotrophic lateral sclerosis (ALS)\n  * poorly controlled diabetes\n  * post-chemo or radiation syndromes\n  * sickle cell anemia\n  * symptomatic Coronary Artery Disease (CAD)\n  * chronic liver disease\n  * chemical insufficiency\n  * morbid obesity (body mass index (BMI) \\>= 40)\n  * human immunodeficiency virus (HIV)\n  * alcohol\u002Fsubstance use disorder\u002Fstimulant\u002Fopioid\u002Fother depressant misuse in the past year\n  * major mental health condition (e.g., psychosis, suicidal ideations, major depressive disorder) that interferes with their ability to accurately report symptoms\n  * hospitalized or undergoing invasive procedures in the past 12 months due to exacerbations of any chronic conditions (such as diabetes, coronary artery disease, hypertension, or emphysema)\n  * elevated liver enzymes (2.5 times upper limit of normal) at baseline visit\n  * estimated glomerular filtration rate less than 60 ml\u002Fmin\u002F1.73 sqm at baseline visit\n  * hemoglobin less than 10 g\u002FL at baseline visit\n  * evidence of poorly controlled chronic conditions listed above, or others that may mimic GWI as per the PI, either by self-report, Veterans Health Administration (VHA) electronic health record information review, laboratory testing or physical examination\n* Changes in medications for chronic conditions in the 3 months preceding enrollment (based on self-report)\n* Suicidal ideation based on their responses on the Columbia Suicide Risk Inventory\n* Prescribed or taking Montelukast in the past 6 months for any reason\n* Taking 2 or more medications with moderate interactions with Montelukast\n* Pregnancy or intention to become pregnant\n* Active homicidal ideation\n* COVID-19 illness (confirmed or suspected) without recovery to pre-COVID health status","70 Years",{"count":164,"type":19},80,[166],"PHASE1","The study addresses the pre-clinical promise of Montelukast (MLK) for improving brain function in veterans with Gulf War Illness (GWI). MLK, a US Food and Drug administration (FDA)-approved drug for asthma, has shown efficacy in an animal model of GWI to improve cognitive and mood function through modulation of leukotriene signaling and suppression of neuroinflammation.",[25],[170],"Montelukast","2025-08-15",{"date":173,"type":35},"2025-08-20",{"date":171,"type":35},{"date":176,"type":19},"2028-08",{"name":72,"class":42},{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":4,"eligibilityCriteria":184,"healthyVolunteers":185,"sex":52,"minAge":186,"maxAge":4,"enrollmentInfo":187,"targetDuration":4,"studyType":189,"phases":4,"briefSummary":190,"conditions":191,"keywords":192,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":204},"100495818","validating-gulf-war-illness-blood-biomarkers-100495818","NCT05736146","Validating Gulf War Illness Blood Biomarkers","Validating Blood Biomarkers of Brain Immune and Metabolic Dysfunction in Gulf War Illness","Inclusion Criteria:\n\n1. Age 35 years or older.\n2. For GWI cases, served in the 1990-1991 Gulf War as active duty, national guard, or reserves and meet criteria for the CDC Chronic Multisymptom Illness (CMI) GWI definition or Kansas GWI definition.\n3. For controls, must be a veteran in the same age range as those veterans with GWI as defined above.\n4. Ability to understand written and spoken English or availability of a legal representative who can understand written or spoken English. Participants and caregiver\u002Finformants must be able to read, write and speak the language in which psychometric tests are provided with visual and auditory acuity (corrected) sufficient to allow for accurate testing.\n\nExclusion Criteria:\n\n1. Diagnosed or being treated by a physician for any of the following (Steele et al, 2000) and deemed clinically significant per the discretion of the PI:\n\n   1. Cancer (except for non-melanoma skin cancers)\n   2. Chronic infectious disease\n   3. Problems resulting from postwar injuries.\n   4. Liver disease\n   5. Lupus\n   6. Multiple sclerosis\n   7. Stroke\n   8. Serious psychiatric condition (those associated with psychosis and\u002For for which the respondent had been hospitalized since 1991).\n   9. Dementia or any type of Parkinson's disease (PD).\n2. Hospitalized in the last 5 years for alcohol or drug dependence, depression, or post-traumatic stress disorder (PTSD).\n3. Female subject is either pregnant or nursing.",true,"35 Years",{"count":188,"type":19},100,"OBSERVATIONAL","The investigators goals are to identify blood lipids\u002Fmetabolites that correlate with cognitive decline in the presence of the APOE ε4 allele among veterans with GWI. To determine the effect of dietary, medical and biological factors that influence lipid and metabolites in blood from GW veterans. To identify blood lipid\u002Fmetabolite profiles that correlate with bioenergetics deficits and glial activation in the brains of GWI. To validate blood biomarker signatures of GWI using APOE genotyping and blood lipids\u002Fmetabolites that correlate with the CNS dysfunction in GWI.",[25,27],[193,194],"Gulf War","APOE","2025-07-21",{"date":197,"type":35},"2025-07-24",{"date":199,"type":35},"2022-06-30",{"date":201,"type":19},"2026-03-01",{"name":203,"class":42},"Roskamp Institute Inc.",3,{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":211,"eligibilityCriteria":212,"healthyVolunteers":11,"sex":52,"minAge":213,"maxAge":162,"enrollmentInfo":214,"targetDuration":4,"studyType":20,"phases":216,"briefSummary":218,"conditions":219,"keywords":220,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":233},"100438322","early-phase-1-gwictic-nac-mechanistic-study-in-gulf-war-veterans-100438322","NCT04987775","GWICTIC: NAC Mechanistic Study in Gulf War Veterans","Mechanisms of Oxidative Stress During N-Acetyl Cysteine (NAC) Supplementation in Veterans With Gulf War Illness (GWI)","NAC","Inclusion Criteria:\n\n* 47 to 70 years\n* Served in the Gulf War Theater for any period between August 1990 and July 1991.\n* Meets modified Kansas case definition criteria for Gulf War Illness. The modified Kansas definition includes the following:\n\n  1. Allowance of normal illness of aging, such as hypertension and diabetes, if the conditions are treated and are in demonstrable stable and normal ranges at the time of screening and assessment.\n  2. Allowance of stable comorbid conditions such as Post Traumatic Stress Disorder (PTSD), Major Depressive Disorder (MDD), and mild Traumatic Brain Injury (mTBI) that have not required hospitalization in the 2 years prior to recruitment. Severe TBI is excluded.\n* Able to provide written consent to the study\n* Agrees to participate in follow-up visits.\n\nExclusion Criteria:\n\n* Self-report of current treated or untreated major depression with psychotic or melancholic features (as determined by self-report and Hamilton Depression Inventory (Ham-D)), schizophrenia, bipolar disorder, delusional disorders, dementias of any type, or a history of central nervous system (CNS) disorders that may affect cognitive function (e.g., epilepsy, stroke, brain tumor, multiple sclerosis, Parkinson's Disease, Alzheimer's disease), or alcoholism or drug abuse\n* Severe claustrophobia or serious difficulty being in an MRI scanner or other enclosed space (MRS substudy only)\n* Presence of ferrous implanted medical devices or metal fragments or objects that are embedded under the skin (MRS substudy only)\n* Current heavy alcohol or tobacco use (self-report). Alcohol consumption not to exceed approximately 15 drinks per week (with a drink defined as 12 oz beer, 5 oz wine, or 1.5 oz distilled spirits) and tobacco use not to exceed 20 cigarettes (or equivalent) per day.\n* Chronic active infections such as HIV, Hepatitis B Virus (HBV), and Hepatitis C Virus (HCV) (self-report or antibody titer)\n* Renal disease (self-report or laboratory results: renal insufficiency with serum creatinine \\> 2.0 mg\u002FdL)\n* Liver disease (self-report or laboratory results: hepatic insufficiency (bilirubin \\>2.5mg\u002FdL or transaminases \\> 3 times the upper limits of normal)\n* Uncontrolled diabetes (HgbA1c \\> 7.5) without adequate medical care. Individuals with HgbA1c \\> 7.5 will be reviewed and judged by the PI or delegate; if potential participant has adequate medical care to manage diabetes, enrollment is allowed; otherwise HgbA1c \\> 7.5 is exclusionary\n* Diagnosed vascular disease (including congestive heart failure)\n* Diagnosed bleeding disorders or use of blood-thinning medications\n* Receipt of stavudine or didanosine for more than 7 days within 30 days prior to screening\n* Currently have exclusionary diagnoses that could reasonably explain the symptoms of their fatiguing illness and their severity\n* Are scheduled for a surgery during the period of study participation or had surgery within 6 weeks prior to screening\n* Pregnant (women only)\n\nProhibited Concomitant or Prior Therapies\n\n* Currently on dialysis\n* Previous or current receipt of any antiviral medication, such as pegylated interferon, ribavirin, entecavir, tenofovir, or didanosine for more than 7 days within 30 days prior to screening\n* Participating in another interventional (including social-behavioral therapy) clinical trial of an investigational therapy within 6 weeks prior to consent, or planning to participate in another interventional clinical trial of an investigational therapy during the course of this study\n* Any herbal medicine within 30 days prior to consent and screening blood draw","47 Years",{"count":215,"type":19},170,[217],"EARLY_PHASE1","This mechanistic study will test if NAC affects chronic oxidative stress and depletion of antioxidants in GWI participants. Blood specimen collection and neuroimaging will be used to determine whether NAC affects serum glutathione (GSH) concentration and oxidative stress in the CNS when compared to placebo.",[25],[221,222,27,223],"CNS Recovery","N-Acetyl Cysteine (NAC)","Placebo","2025-07-02",{"date":226,"type":35},"2025-07-08",{"date":228,"type":35},"2023-11-30",{"date":230,"type":19},"2026-04",{"name":232,"class":42},"Nova Southeastern University",7,{"id":235,"slug":236,"hasResults":11,"nctId":237,"briefTitle":238,"officialTitle":238,"acronym":4,"eligibilityCriteria":239,"healthyVolunteers":11,"sex":52,"minAge":80,"maxAge":240,"enrollmentInfo":241,"targetDuration":4,"studyType":20,"phases":243,"briefSummary":244,"conditions":245,"keywords":246,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":204},"100491188","phase-3-confirmation-of-diet-as-a-treatment-for-gulf-war-illness-100491188","NCT05675878","Confirmation of Diet as a Treatment for Gulf War Illness","Inclusion Criteria:\n\n* Males and Females of all races and ethnicities who are ≤75 yrs of age\n* Served in the 1990-1991 Persian Gulf War\n* Fulfill both Center for Disease Control (CDC) and Kansas definitions of Gulf War Illness\n* Stable medication regimen for ≥1 month and willing to keep medications and supplements stable throughout study participation\n\nExclusion Criteria:\n\n* Recent substance use disorder (past year)\n* Unwilling to stop using alcohol, tobacco (including vaping) and\u002For marijuana; or unwilling to change diet\n* Diagnosed seizure disorder or severe asthma requiring past hospitalization\n* Currently taking medication which affects glutamatergic or GABAergic neurotransmission (but can work with their physician to wean off of these medications prior to participating)","75 Years",{"count":242,"type":19},160,[84],"This clinical trial aims to confirm previous findings from a smaller study which demonstrated significant improvements in all symptoms among veterans with Gulf War Illness after one month on the dietary intervention. The main objectives of this study are: 1) to confirm previous findings of treatment response to the diet in a larger and more diverse group; 2) to examine how changes in the nervous system may be the reason for improvement; and 3) to identify markers which change in the blood after one month on the diet. Participants will have baseline measures collected and then will be randomized into the intervention or wait-listed control group, which they will follow for one month before being reassessed.",[25,27],[27,247,25,248,249],"GWI","Diet","Treatment","2024-07-05",{"date":252,"type":35},"2024-07-09",{"date":254,"type":35},"2023-03-01",{"date":256,"type":19},"2025-12-30",{"name":258,"class":42},"American University"]